Anna Maria Di Giacomo

Anna Maria Di Giacomo, MD
Associate Professor of Oncology, University of Siena
Chair, Early Phase Clinical Trial Center and  Associate Director, Center for Immuno-Oncology, Department of Oncology, University Hospital of Siena, Italy

Anna Maria Di Giacomo is Associate Professor of Oncology at the University of Siena, Chair of the Early Phase Clinical Trial Center and Associate Director of the Center for Immuno-Oncology, Department of Oncology at the University Hospital of Siena. She is a member of the Associazione Italiana di Oncologia Medica (AIOM), the Italian Network for Tumour Biotherapy (NIBIT), The Italian Melanoma Intergroup (IMI), European Society of Clinical Oncology (ESMO) and America Society of Clinical Oncology (ASCO). She is member of Board of Director of NIBIT Foundation and of the Federation of Italian Cooperative Oncology Groups (FICOG) and IMI. She is member of the Scientific Committee of ESMO Immuno-oncology Meeting. Prof. Di Giacomo is currently Principal Investigator and Co-Investigator for more than 180 clinical trials in solid malignancies, investigating bio-chemotherapy, immunotherapeutic agents and molecularly targeted agents. Prof. Di Giacomo’s translational research interests include: the immunological and clinical activity of immunotherapeutic agents including the new generation of targeted immunotherapy in the treatment of skin, brain and other solid tumours; epigenetics and epigenetic-immuno-sequencing strategies to improve efficacy of cancer immunotherapy.